QCG
RUBY

Quadrant Capital Group’s Rubius Therapeutics, Inc RUBY Stock Holding History

Quadrant Capital Group’s Portfolio RUBY Stock Details RUBY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-162
Closed -$1K – 2830
2022
Q1 		$1K Buy
+162
New +$1.03K ﹤0.01% 2454

Other funds holding RUBY

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AFM
Abbot Financial Management Andover, Massachusetts $239M AUM 27.19% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Quadrant Capital Group's RUBY Position: Q2 2022 in Review

Quadrant Capital Group sold out of Rubius Therapeutics, Inc (RUBY) in Q2 2022, closing a stake of 162 shares — an estimated $1K sold.

Quadrant Capital Group first reported a position in RUBY in Q1 2022 and held it in 1 quarter. The position peaked at $1K in Q1 2022. 72 funds tracked by Wall St. Rank hold RUBY as of Q2 2022.

  • Quadrant Capital Group reported no remaining Rubius Therapeutics, Inc position as of Q2 2022 after selling out during the quarter.
  • Quadrant Capital Group sold 162 Rubius Therapeutics, Inc shares in Q2 2022, an estimated $1K.
  • Quadrant Capital Group first reported a position in Rubius Therapeutics, Inc in Q1 2022 and held it in 1 quarter.
  • Quadrant Capital Group's Rubius Therapeutics, Inc position peaked at $1K in Q1 2022.
  • 72 funds tracked by Wall St. Rank held Rubius Therapeutics, Inc as of Q2 2022.

Based on Quadrant Capital Group's 13F filing for Q2 2022, filed 9 Aug 2022.